Description: Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Home Page: www.catalent.com
14 Schoolhouse Road
Somerset,
NJ
08873
United States
Phone:
732 537 6200
Officers
| Name | Title |
|---|---|
| Mr. John R. Chiminski | Exec. Chair of the Board |
| Mr. Alessandro Maselli | CEO & Director |
| Mr. Thomas P. Castellano | Sr. VP & CFO |
| Mr. Steven L. Fasman Esq. | Exec. VP, Corp. Sec. & Chief Admin. Officer |
| Dr. Aristippos Gennadios Ph.D. | Group Pres of Pharma & Consumer Health Segment |
| Mr. Ricky Hopson | Pres & Division Head for Clinical Devel. and Supply |
| Ms. Karen Murphy Santiago | VP & Chief Accounting Office |
| Mr. Julien Meissonnier | VP & Chief Scientific Officer |
| Mr. Charles Lickfold | Sr. VP & Chief Information Officer |
| Mr. Paul Surdez | VP of Investor Relations |
Exchange: F
Country: DE
Currency: Euro (€)
| Forward PE: | 13.1062 |
|---|---|
| Trailing PE: | 20.1283 |
| Price-to-Book MRQ: | 1.7608 |
| Price-to-Sales TTM: | 1.574 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 19000 |